Glad you note it is incredibly undervalued which we all know. Are you still claiming we are headed into PH3 for a once a day Oxycontin or just the studies required for ANDA and 505B2 submissions? I believe the once a day Oxycontin will come later but it could happen.
Perhaps that is why Actavis is partnered with Elite on a 505B2 product through Mikah? Or do you think that product is a different abuse resistant opioid?
And this one doesn't either. Market cap 25M LOL LOL
So the market cap is 25 million.......guess that'll change when Elite puts out its first abuse resistant product--and why I am buying all the shares I can get my hands on NOW bc the market cap is 25 million and not 1 Billion as it has the potential to do IMO :-)
Market Data 
Markets 
AI
